PBYI — Puma Biotechnology Balance Sheet
0.000.00%
- $351.05m
- $276.04m
- $228.37m
Annual balance sheet for Puma Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 82.1 | 81.1 | 95.9 | 101 | 97.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 32.5 | 42.3 | 47.8 | 32 | 53.7 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 140 | 134 | 156 | 148 | 163 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.8 | 12.5 | 8.65 | 5.09 | 5.56 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 227 | 222 | 231 | 213 | 216 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 110 | 77.5 | 99.4 | 96.1 | 81.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 229 | 200 | 177 | 121 | 86 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2.45 | 21.6 | 53.4 | 92.1 | 130 |
| Total Liabilities & Shareholders' Equity | 227 | 222 | 231 | 213 | 216 |
| Total Common Shares Outstanding |